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Abstract
Background and objective: This study examined whether zinc intake was associated with lower risk of smoking-
induced obstructive lung disorder through interplay with cadmium, one of major toxicants in cigarette smoke.
Methods: Data were obtained from a sample of 6,726 subjects aged 40+ from the Third National Health and Nutrition 
Examination Survey. The forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured 
using spirometry. Gender-, ethnicity-, and age-specific equations were used to calculate the lower limit of normal (LLN) 
to define obstructive lung disorder as: observed FEV1/FVC ratio and FEV1 below respective LLN. Zinc intake was 
assessed by questionnaire. Logistic regression analysis was applied to investigate the associations of interest.
Results: The analyses showed that an increased prevalence of obstructive lung disorder was observed among 
individuals with low zinc intake regardless of smoking status. The adjusted odds of lung disorder are approximately 1.9 
times greater for subjects in the lowest zinc-intake tertile than those in the highest tertile (odds ratio = 1.89, 95% 
confidence interval = 1.22-2.93). The effect of smoking on lung function decreased considerably after adjusting for 
urinary cadmium. Protective association between the zinc-to-cadmium ratio (log-transformed) and respiratory risk 
suggests that zinc may play a role in smoking-associated lung disorder by modifying the influence of cadmium.
Conclusions: While zinc intake is associated with lower risk of obstructive lung disorder, the role of smoking cession 
and/or prevention are likely to be more important given their far greater effect on respiratory risk. Future research is 
warranted to explore the mechanisms by which zinc could modify smoking-associated lung disease.
Background
Obstructive lung disorders including chronic obstructive 
pulmonary disease (COPD) are characterized by chronic 
airway inflammation and ensuing airflow limitation. 
Although cigarette smoking is the most important risk 
factor for obstructive lung disease, the underlying mecha-
nisms are still not completely understood. For instance, it 
has been suggested that COPD results from smoking-
associated inflammation and oxidative damage to key 
enzymes (e.g., alpha 1-antitrypsin deficiency) [1], but not 
all smokers develop COPD [2], and some former smokers 
have persistent inflammation and remain at risk [3].
Both animal and human epidemiologic data indicate that 
exposure to cadmium (Cd), a constituent of cigarette 
smoke, is associated with oxidative stress and chronic 
inflammation [4-7]. Increasing evidence indicates that Cd 
may play a role in smoking-induced disorders including 
impaired lung function [8,9], diabetes and hypertension 
[10-12]. Of note, once entering the body, Cd is trans-
ported in the blood and bound to plasma proteins, mainly 
metallothionein [13], a cysteine rich protein and scaven-
ger of OH radical [14]. Thus the binding of metallothion-
ein with Cd is an essential adaptation to Cd poisoning 
because it can prevent free Cd ions from exerting their 
toxicity [15]. The resulting metallothionein mediated 
reduction in Cd toxicity however, potentially comes at the 
expense of lowering the reserve capacity for buffering OH 
radicals; thus exposing tissues to oxyradical damage from 
other sources [16].
Given zinc (Zn) is a trace element and an effective 
inducer of metallothionein, we proposed the hypothesis 
that the risk of developing smoking-associated obstruc-
tive lung disease could be modified by Zn intake through 
modification of Cd toxicity. To test this hypothesis, we 
evaluated whether the association between obstructive 
lung disorders and cigarette smoking varies with dietary 
* Correspondence: jouweilin@yahoo.com
4 Cardiovascular Center and Health Management Center, National Taiwan 
University Hospital Yun-Lin Branch, Dou-Liou City, Taiwan
Full list of author information is available at the end of the article© 2010 Lin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Lin et al. Respiratory Research 2010, 11:53
http://respiratory-research.com/content/11/1/53
Page 2 of 8Zn intake, accounting for other risk factors. The analysis 
was conducted using a population-based, nationally rep-
resentative sample from the Third National Health and 
Nutrition Examination Survey (NHANES III, 1988-94).
Materials and methods
Data source and study population
The NHANES is a series of national health examination 
surveys, conducted by the National Center for Health 
Statistics (NCHS) of the Center for Disease Control and 
Prevention, to collect data on the health and nutritional 
status of a representative sample of the non-institutional-
ized civilian US population by using a multistage, strati-
fied sampling design [17]. The protocol was approved by 
the NCHS Research Ethics Review Board (ERB) and all 
subjects provided written informed consent. The analysis 
of this study was restricted to 8,745 non-Hispanic 
Whites, non-Hispanic Blacks, and Mexican Americans 
aged 40 yrs or older with valid spirometry measurements 
in the NHANES III survey (1988-94). A total of 868 sub-
jects with missing information for covariates of interest 
(e.g., urinary Cd) were excluded from the analyses. Preg-
nant subjects (n = 65) and those with unreliable or 
incomplete information on Zn intake, such as type, fre-
quency, and amount of vitamin and mineral supplement 
use (n = 1,086) were excluded. This resulted in a final 
sample of 6,726 subjects in the current analysis.
Lung function measurement and Definition of obstructive 
lung disorders
Lung function was assessed with standard determina-
tions of the forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC) with dry rolling-seal 
spirometer (Ohio 827 rolling seal spirometer; Ohio Medi-
cal Instrument Company, Cincinnati, Ohio) following the 
procedures described by the American Thoracic Society 
(ATS) in 1987 [18]. The largest FVC and FEV1 obtained 
from acceptable maneuvers were used for the analysis. As 
suggested by ATS and European Respiratory Society 
(ERS) [19], the predicted values for the lower limit of nor-
mal (LLN) of the FEV1/FVC ratio and FEV1 were calcu-
lated for each subject using gender-, ethnicity-, and age-
specific equations reported by Hankinson et al. (1999) 
[20]. In the current analysis, the subject was categorized 
as having obstructive lung disorder if his/her observed 
FEV1/FVC ratio and FEV1 were less than respective LLN 
[20,21].
Collection of demographic, dietary, and laboratory data
Self-reported demographic characteristics including age, 
gender, body mass index (BMI), race/ethnicity, and ciga-
rette smoking status were obtained during the survey 
interview. BMI was calculated from measured height and 
weight, and categorized as underweight (<18.5 kg/m2), 
normal (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), 
and obese (? 30 kg/m2) [22]. Smoking status was classified 
as: never-smokers (<100 life time cigarettes), former 
smoker (> = 100 but not currently smoking), and current 
smoker (> = 100 and current smoking) [23]. The average 
time of smoking cession for former smokers was 18.2 
years (range: <1 - 87 years)(data not shown). Pack-years 
of smoking was also determined as the reported average 
number of packs smoked per day by the number of years 
smoked (1 pack-year = 20 cigarettes/day for 1 year). The 
concentrations of serum cotinine (the metabolite of nico-
tine) were also measured from all subjects using high per-
formance liquid chromatography (HPLC)-atmospheric 
pressure chemical ionization tandem mass spectrometry 
[24] to control for environmental smoking.
Dietary intake data were collected by trained interviewers 
using an automated NHANES III Dietary Data Collection 
System described previously [25]. In brief, total intake of 
daily Zn was estimated by summing dietary Zn intake 
from food, beverage and supplements (vitamins and min-
eral products used during the past month) assessed by 
24-hr dietary recall and food-frequency interviews. Uri-
nary Cd concentration, commonly used to characterize 
cadmium exposure [26,27], was measured using Zeeman 
graphite furnace atomic absorption spectrometry (Per-
kin-Elmer Corp., Norwalk, CT) [24] with a detection 
limit of 0.01 ?g/L and was adjusted for urinary creatinine 
[28,29].
Statistical analyses
To investigate the role of Zn intake in smoking-related 
lung disorder, the differences in prevalence of obstructive 
lung disorder across demographic characteristics were 
first assessed with Cochran-Mantel-Haenszel chi-square 
tests. The odds ratios (OR) with 95% confidence interval 
(95% CI) generated from logistic regression models were 
then used to examine the association of interests. The 
interactions of zinc intake with smoking and cadmium 
exposure were also examined, and the chi-squared trend 
test was used to evaluate whether there were trends in the 
odds ratios across categories of zinc intake and cigarette 
smoking/cadmium exposure. Logarithmic transforma-
tions were performed to normalize the data distribution 
where necessary. We applied mobile examination center 
(MEC)/home-examined statistical sampling weight to 
account for the complex stratified multistage sampling in 
NHANES III and used SUDAAN 9.03 (Research Triangle 
Institute, 2004) with the Taylor series linearization 
method [30] to obtain unbiased standard errors for all 
statistical analyses. Thus, the percentages and regression 
estimates reported here represent estimates for the U.S. 
population. Tertile cutoffs of dietary Zn and urinary Cd 
were determined according to the weighted distribution 
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was set at 0.05.
Results
The crude prevalence of obstructive lung function by 
demographic characteristics of the participants aged 40 
years or older is shown in table 1. As expected, the preva-
lence of obstructive lung disorder increased in the order: 
never-smokers (2.99%) < former smokers (9.55%) < active 
smokers (17.7%). A similar pattern of results was evident 
for pack-years of cigarettes as: zero pack-years (3.08%) < 
greater than zero-19 pack years (6.50%) < greater than 20 
pack-years (19.6%). Individuals with low Zn intake (in the 
low tertile of Zn intake < 8.35 mg/day) had higher preva-
lence of obstructive lung disorder than did those with 
middle (8.35-14.4 mg/day) and high (> 14.4 mg/day) Zn 
intake (p = 0.01). The geometric mean and 5th-to-95th 
percentile range for daily Zn intake were 11.0 and 4.09-
34.4 mg/day, respectively (data not shown). Also, 
obstructive lung disorder was generally more prevalent 
among elderly and non-Hispanic whites. For instance, the 
prevalence of individuals with obstructive lung function 
among those aged 55 years or older was approximately 
twice that of subjects aged 40-54. BMI was inversely asso-
Table 1: Prevalence of obstructive lung disorder by demographic characteristics
Characteristics N Prevalence of obstructive lung
function (95%CI)a
P-valueb
Smoking status < 0.001
Never-smokers 2948 2.99 (2.14-4.16)
Former smokers 2306 9.55 (7.77-11.7)
Active smokers 1472 17.7 (15.2-20.6)
Pack years of cigarettes < 0.001
0 3171 3.08 (2.24-4.23)
>0-19 1874 6.50 (5.05-8.33)
? 20 1681 19.6 (16.7-22.9)
Zinc intake, mg/d 0.01
Tertile 1 (< 8.35) 2464 11.4 (8.78-14.7)
Tertile 2 (8.30-14.4) 2135 8.66 (6.99-10.7)
Tertile 3 (>14.4) 2127 6.60 (5.39-8.07)
Age, yrs < 0.001
40-54 2484 5.97 (4.38-8.10)
55 or older 4242 11.5 (10.2-12.9)
Gender 0.16
Male 3288 9.55 (8.06-11.3)
Female 3438 8.13 (6.62-9.94)
Race/Ethnicity < 0.001
Mexican American 1522 4.86 (3.70-6.37)
Non-Hispanic black 1500 5.58 (4.09-7.57)
Non-Hispanic white 3704 9.26 (7.93-10.8)
Body mass index, kg/m2 0.001
<18.5 106 33.9 (20.0-51.3)
18.5-24.9 2120 9.80 (7.66-12.5)
25-29 2634 7.96 (6.59-9.60)
? 30 1866 7.10 (5.87-8.57)
a Obstructive lung disorder was defined as: observed FEV1/FVC ratio < [FEV1/FVC]LLN and observed FEV1 < [FEV1]LLN [20,21]. The estimated 
prevalence of obstructive lung disorder was calculated using the NHANES III sample weights.
b Cochran-Mantel-Haenszel chi-square test.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced volume vital capacity; LLN, lower limit of normal.
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cantly increased among underweight subjects (BMI less 
than 18.5) as compared to subjects with higher BMI. The 
relationship of obstructive lung disorder with low body 
weight may represent existing poor health in this sub-
group. Overall, the age-adjusted (2000 U.S. population) 
prevalence of obstructive lung disease among U.S. adults 
aged 40+ was 8.63% (95% CI = 7.39-10.1%, data not 
shown).
When all of the covariates were considered jointly in a 
multiple logistic regression model on obstructive lung 
disease, the protective effect of Zn intake remained sig-
nificant (table 2). For instance, as shown in model 1, those 
who currently had lowest Zn intake were twice as likely to 
have obstructive lung disorder compared to those with 
the highest tertile of Zn intake after adjustment for cova-
riates (OR = 1.97, 95% CI = 1.28-3.03). Of other risk fac-
tors examined in the study, cigarette smoking is the 
leading cause of obstructive lung disorder, followed by 
BMI, age, and race-ethnicity. Comparable results were 
obtained by replacing smoking status with pack years of 
cigarettes (Additional file 1).
Interestingly, the effect (estimated OR) of smoking on the 
obstructive lung disorder decreased approximately 20-
40% in model 2 as compared to model 1. Whereas the 
influence of Zn on respiratory risk remained the same, 
the odds ratios for both smoking status and urinary Cd 
were reduced by another 15-50% with further adjustment 
of pack years of cigarettes (data not shown). Indeed, pack 
years of cigarettes, urinary Cd, and smoking status were 
significantly correlated with each other. For instance, uri-
nary Cd was associated with both pack years of cigarettes 
(Spearman correlation = 0.34, p < 0.001, data not shown) 
and cigarette smoking status that the geometric means 
(standard error) for urinary Cd were 0.87 (0.04), 0.53 
(0.02), and 0.36 (0.02) ?g/g creatinine in active smokers, 
former smokers, and never-smokers, respectively (p < 
0.001, data not shown). On the other hand, the cadmium 
effect on obstructive lung disorder is also significant and 
is independent of smoking (model 2). Despite the lack of 
statistical significance for either Zn-smoking (p = 0.68) or 
Zn-Cd interactions (p = 0.06) (data not shown), there are 
positive trends in the odds ratios among individuals who 
had low Zn intake across all smoking status categories 
(figure 1a), or urinary cadmium concentrations (figure 
1b) (Ptrend < 0.05 for both). In addition, there was an 
inverse relationship between Zn intake and urinary Cd 
following adjustment for other covariates (the estimated 
regression coefficient ± standard error = -0.097 ± 0.023, p 
< 0.001, data not shown). The plot of an adjusted log-
odds of obstructive lung disorder versus the ratio of Zn to 
Cd suggested that higher ratios were in fact protective 
(figure 2). These results indicate that Zn may moderate 
the toxic role of Cd in cigarette smoking.
Discussion
While the current findings are consistent with earlier 
studies suggesting that smoking is the leading cause of 
obstructive lung disease in the U.S. population aged 40+ 
[31,32], we also found that Zn intake is associated with 
lower risk of obstructive lung disorder across cigarette 
smoking status. The effect persisted even after adjust-
ment for other respiratory risk factors such as age. Of 
note, the negative effect of cigarette smoking on obstruc-
tive lung disorder decreased after adjusting for urinary 
Cd in the multivariable analyses. Indeed, cigarette smok-
ing is one of the major sources of environmental exposure 
to Cd [33,34]. It has been suggested that Cd plays an 
important role in promoting oxidative stress and inflam-
mation [5,6]. The current findings support the prior evi-
dence suggesting that cadmium exposure, as a risk factor 
independent of cigarette smoking, is associated with 
impaired lung functions and presumably other cadmium-
associated diseases such as cardiovascular disease [8,35]. 
Considering its 10-30 year half-life in the body compared 
to other shorter lived constituents of cigarette smoke 
[13,36], Cd might reasonably explain some of the sus-
tained obstructive lung disorder observed among former 
smokers who had not smoked in years [3].
The current analyses reveal a protective association 
between the zinc-to-cadmium ratio (log-transformed) 
and reduced respiratory risk suggesting that Zn may 
moderate the risk of smoking-associated lung disorders 
through interplay with Cd. Zn is essential to the produc-
tion of metallothionein, a key component in the detoxifi-
cation kinetics of Cd in the human body [13,14]. 
Metallothionein alone can passively extract the interfer-
ing Cd and reduce its toxic load directly. The inverse 
association between Zn and Cd adds support to the 
hypothesis that when sufficient Zn is available, metal-
lothionein not only extracts the offending Cd, but actively 
restores structure and function by donating the missing 
Zn [37]. Alternatively, the positive influence of Zn may 
also result from the anti-inflammatory and anti-oxidant 
activities of a spectrum of Zn-dependent enzymes and 
transcription factors [38,39]. It was found, for instance, 
reported that zinc can decrease the production of inflam-
matory cytokines such as tumor necrosis factor-? (TNF-
?) and interleukin-1? (IL-1?) via inhibition of NF-kappaB 
activation [38].
The current findings were generally compatible with the 
U.S. Recommended Dietary Allowances (RDAs) for Zn 
intake at 11 and 8 mg/day for men and women aged 19+, 
respectively [40]. Adequate intake of Zn is associated 
with lower risk of obstructive lung disease, presumably 
through mitigation of inflammatory and oxidative 
stresses associated Cd exposure. A potential benefit of 
higher Zn intake may exist for former smokers, who dem-
onstrate a consistent trend toward lower risk at higher Zn 
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an important clearance mechanism. Although the most 
appropriate Zn intake related to a lower risk of obstruc-
tive lung disorder is unclear, the increased respiratory 
risk of low Zn intake is apparent even in never smokers.
There were several limitations of the current study that 
need to be addressed. First, the cross-sectional design of 
NHANES data only permits the investigation of associa-
tions rather than causation among Cd, Zn, smoking, and 
obstructive lung disease. The results, nevertheless, were 
biologically plausible and supported by epidemiologic 
and animal data [15,38]. Future work with a longitudinal 
follow-up design would help verify these findings. Sec-
ond, despite its demonstrated validity as a reliable mea-
surement of food intake [41,42], the 24-hour recall and 
self-reported dietary supplement data may not provide a 
precise estimation of Zn intake. When available, serum or 
urinary Zn levels, which were not measured in NHANES 
III, could help clarify the role of Zn in smoking-associ-
ated lung disease. Finally, although we adjusted for a 
number of confounding factors, such as age, the con-
founding influences of unmeasured factors (e.g. genetic 
background) cannot be excluded. For instance, tumor 
necrosis factor-alpha (TNF-?) and interleukin-10 (IL-10) 
represent pro- and anti-inflammatory cytokines, respec-
tively, and polymorphisms in TNF-? and IL-10 have been 
associated with obstructive lung disease [43,44], a com-
plex disease characterized by airway obstruction and 
Table 2: Multivariate-adjusted logistic regression of obstructive lung disorder using smoking status as the measure of 
tobacco exposure
Model 1b Model 2b
OR (95% CI) p OR (95% CI) p
Smoking status < 0.001 < 0.001
Never-smokers 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Former smokers 3.37 (2.21-5.14) 2.60 (1.67-4.06)
Active smokers 7.66 (4.97-11.79) 4.38 (2.71-7.08)
Zinc intake, mg/d 0.01 0.01
Tertile 1 (< 8.35) 1.97 (1.28-3.03) 1.89 (1.22-2.93)
Tertile 2 (8.30-14.4) 1.36 (0.95-1.96) 1.29 (0.91-1.82)
Tertile 3 (>14.4) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Age, yrs (55 or older) 2.39 (1.75-3.25) < 0.001 1.82 (1.33-2.49) < 0.001
Gender (male) 1.13 (0.84-1.53) 0.38 1.37 (0.99-1.89) 0.05
Race/Ethnicity < 0.001 0.001
Mexican American 0.61 (0.42-0.88) 0.61 (0.41-0.89)
Non-Hispanic black 0.45 (0.30-0.69) 0.47 (0.31-0.73)
Non-Hispanic white 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Body mass index, kg/m2 0.001 0.001
<18.5 3.99 (1.81-8.79) 3.63 (1.72-7.63)
18.5-24.9 1.00 (1.00-1.00) 1.00 (1.00-1.00)
25-29 0.83 (0.62-1.11) 0.81 (0.60-1.11)
? 30 0.78 (0.56-1.08) 0.79 (0.56-1.11)
Urinary cadmium, ?g/g creatinine 0.001
Tertile 1 (< 0.39) - 1.00 (1.00-1.00)
Tertile 2 (0.39-0.79) - 1.54 (0.98-2.43)
Tertile 3 (>0.79) - 3.48 (2.54-4.76)
a Obstructive lung disorder was defined as: observed FEV1/FVC ratio < [FEV1/FVC]LLN and observed FEV1 < [FEV1]LLN [20,21]. The estimated 
prevalence of obstructive lung disorder was calculated using the NHANES III sample weights.
b Both model 1 and 2 accommodated smoking status, zinc intake, and other covariates including age, gender, race/ethnicity, and body mass 
index, whereas model 2 was further adjusted for urinary cadmium.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced volume vital capacity; LLN, lower limit of normal.
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Figure 1 Adjusted odds ratios for obstructive lung disorder by (A) smoking status and daily zinc intake (adjusted for age, body mass index, 
gender, race/ethnicity, and urinary cadmium); (B) urinary cadmium and daily zinc intake (adjusted for age, body mass index, gender, race/
ethnicity, and smoking status).
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anti-inflammatory responses could well determine pro-
tection from or susceptibility to the pathogenesis of 
obstructive lung disease such as COPD [45].
In conclusion, the current study demonstrated that Zn 
intake is associated with lower a risk of developing smok-
ing-associated obstructive lung disorder for smokers and 
non-smokers alike. The interplay between Zn and Cd 
presumably plays a role in mediating the toxic effect of 
smoking. Although Zn intake is associated with lower 
risk of obstructive lung disease, the risk reduction associ-
ated with smoking cessation or never smoking is much 
greater. Thus, smoking prevention and cessation pro-
grams should remain a cornerstone of public health pol-
icy to reduce the subsequent risk of obstructive lung 
disease.
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